Based in Cambridge, Massachusetts, Biogen is focused on the development and marketing of therapies for people living with serious neurological and neurodegenerative diseases. The company has a leading portfolio of drugs to treat MS symptoms, including Tecfidera and Tysabri.
“Biogen’s commitment to improving outcomes for people living with MS spans more than two decades, during which time we’ve fundamentally changed the treatment of the disease. We are now applying our expertise in neurology to discover and develop new therapies to address some of the most challenging and complex diseases of the brain,” Alfred Sandrock, executive vice president and chief medical officer at Biogen, said in a press release.
Tecfidera is the world’s most prescribed oral therapy for relapsing forms of MS. Several clinical trials have proven its effectiveness in reducing the rate of MS relapses and slowing disease progression, although the mechanisms of the drug are still unclear. Researchers believe that its beneficial effects are mediated through antioxidant and anti-inflammatory activities.
One of Biogen’s presentations at AAN 2017, titled “Tecfidera modulates short term metabolomic signatures in people with multiple sclerosis,” will show results confirming that Tecfidera treatment induces alterations in blood metabolites that are consistent with an antioxidant activity. This finding suggests that Tecfidera inhibits MS progression via protection of neurological tissues from oxidative damage.
Available for more than 10 years, Tysabri is an antibody that selectively blocks the activity of inflammatory cells in MS patients. Its mechanism of action impairs the migration of immune cells to the sites of inflammation. Although it is a proven drug in the battle against MS, the specific mechanism by which Tysabri exerts its effects have not been fully defined.
The Tysabri Observational Program (TOP) (NCT00493298), an ongoing 10-year observational study providing long-term data on relapsing-remmiting MS (RRMS) patients undergoing treatment in clinical practice settings, aims to evaluate Tysabri’s long-term effects and safety.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?